UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7

Benzinga Newsdesk www.benzinga.com Positive 60.3%

Neg 0% Neu 0% Pos 60.3%

UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $4 to $7.